Q1 2025 Immunovia AB (publ) Earnings Call Transcript
Key Points
- Immunovia AB (FRA:1YR) is transitioning from product development to commercialization, preparing to launch their PancreaSure test in September 2025.
- The Verify study showed strong results with 77% sensitivity and 88% specificity in detecting early-stage pancreatic cancer, outperforming traditional imaging methods.
- The company is actively engaging with strategic partners and advocacy groups to support the launch and dissemination of the PancreaSure test.
- Immunovia AB (FRA:1YR) has a fully operational CLA accredited lab in the United States, supporting their commercial launch efforts.
- The company has a robust pipeline of clinical studies, including those funded by the National Institutes of Health, to support reimbursement and further validate their test.
- Immunovia AB (FRA:1YR) faces potential cost increases due to tariffs on biomarker reagents sourced from Europe.
- The company has a limited cash runway, with current funds expected to last only until late Q3 2025, necessitating additional financing.
- There is uncertainty around securing Medicare reimbursement, which is crucial for the test's commercial success in the US market.
- Foreign exchange fluctuations, particularly between the Swedish krona and the US dollar, pose financial risks.
- The company is in the early stages of commercialization and still needs to establish a strong market presence and secure a commercial partner.
()-
Thank you very much.
This is Jeff Borcherding, CEO of Immunovia. I'm very excited that you've chosen to join us today and I want to thank those who have taken the time to learn more about Immunovia and our exciting progress over the first quarter.
As we continue on our journey of saving lives through early detection in pancreatic cancer, this first quarter marked an important turning point for the company as we transitioned from product development and a focus on the product and clinical development and transition to a focus on commercialization and preparing to launch our test later on this year.
Before we jump into the presentation, I'd like to share a brief story.
It's about a woman who reached out to me a few weeks ago. She is a young woman in her 40s. She has a family and also has a family history of pancreatic cancer. She lost her mother to pancreatic cancer at a fairly young age. As you can imagine, this has caused quite a bit of anxiety for her as well as for her
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
